19800611

Source:http://linkedlifedata.com/resource/pubmed/id/19800611

Download in:

Switch to

Custom View

Named Graph Language Inference

Statements in which the resource exists as a subject.
Predicate	Object
rdf:type	pubmed:Citation
lifeskim:mentions	umls-concept:C0023981, umls-concept:C0206034, umls-concept:C0242383, umls-concept:C0796392, umls-concept:C1274040, umls-concept:C1566537
pubmed:issue	6
pubmed:dateCreated	2009-11-25
pubmed:databankReference	http://linkedlifedata.com/resource/pubmed/xref/ISRCTN/ISRCTN73359806
pubmed:abstractText	To report early outcomes of a prospective, double-masked, controlled trial comparing bevacizumab (Avastin; Genentech Inc, South San Francisco, California, USA) to ranibizumab (Lucentis; Genentech Inc) for the treatment of age-related macular degeneration.
pubmed:commentsCorrections	http://linkedlifedata.com/resource/pubmed/commentcorrection/19800611-20399931, http://linkedlifedata.com/resource/pubmed/commentcorrection/19800611-20670740
pubmed:language	eng
pubmed:journal	http://linkedlifedata.com/resource/pubmed/journal/0370500
pubmed:citationSubset	AIM
pubmed:chemical	http://linkedlifedata.com/resource/pubmed/chemical/Angiogenesis Inhibitors, http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Monoclonal, http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Monoclonal, Humanized, http://linkedlifedata.com/resource/pubmed/chemical/Vascular Endothelial Growth Factor A, http://linkedlifedata.com/resource/pubmed/chemical/bevacizumab, http://linkedlifedata.com/resource/pubmed/chemical/ranibizumab
pubmed:status	MEDLINE
pubmed:month	Dec
pubmed:issn	1879-1891
pubmed:author	pubmed-author:AbediGelarehG, pubmed-author:AhmedEdnanE, pubmed-author:BhatiaSumitS, pubmed-author:DalyMaryM, pubmed-author:FeinbergEdwardE, pubmed-author:HouraniehAntounA, pubmed-author:KimWonW, pubmed-author:NessStevenS, pubmed-author:NguyenMaileahM, pubmed-author:SubramanianManju LML
pubmed:issnType	Electronic
pubmed:volume	148
pubmed:owner	NLM
pubmed:authorsComplete	Y
pubmed:pagination	875-82.e1
pubmed:dateRevised	2011-11-17
pubmed:meshHeading	pubmed-meshheading:19800611-Aged, pubmed-meshheading:19800611-Aged, 80 and over, pubmed-meshheading:19800611-Angiogenesis Inhibitors, pubmed-meshheading:19800611-Antibodies, Monoclonal, pubmed-meshheading:19800611-Antibodies, Monoclonal, Humanized, pubmed-meshheading:19800611-Boston, pubmed-meshheading:19800611-Double-Blind Method, pubmed-meshheading:19800611-Female, pubmed-meshheading:19800611-Follow-Up Studies, pubmed-meshheading:19800611-Hospitals, Veterans, pubmed-meshheading:19800611-Humans, pubmed-meshheading:19800611-Injections, pubmed-meshheading:19800611-Male, pubmed-meshheading:19800611-Middle Aged, pubmed-meshheading:19800611-Prospective Studies, pubmed-meshheading:19800611-Retina, pubmed-meshheading:19800611-Tomography, Optical Coherence, pubmed-meshheading:19800611-Treatment Outcome, pubmed-meshheading:19800611-Vascular Endothelial Growth Factor A, pubmed-meshheading:19800611-Visual Acuity, pubmed-meshheading:19800611-Vitreous Body, pubmed-meshheading:19800611-Wet Macular Degeneration
pubmed:year	2009
pubmed:articleTitle	Bevacizumab vs ranibizumab for age-related macular degeneration: early results of a prospective double-masked, randomized clinical trial.
pubmed:affiliation	Veterans Affairs Boston Healthcare System, Jamaica Plain, Massachusetts, USA. manju.subramanian@bmc.org
pubmed:publicationType	Journal Article, Comparative Study, Research Support, U.S. Gov't, Non-P.H.S., Randomized Controlled Trial